MA41111B1 - Compositions anticancéreuses - Google Patents
Compositions anticancéreusesInfo
- Publication number
- MA41111B1 MA41111B1 MA41111A MA41111A MA41111B1 MA 41111 B1 MA41111 B1 MA 41111B1 MA 41111 A MA41111 A MA 41111A MA 41111 A MA41111 A MA 41111A MA 41111 B1 MA41111 B1 MA 41111B1
- Authority
- MA
- Morocco
- Prior art keywords
- hpmcas
- arn
- meth
- acrylate
- prostate cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000001093 anti-cancer Effects 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 6
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 abstract 6
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 abstract 6
- 229920001577 copolymer Polymers 0.000 abstract 5
- 229920000193 polymethacrylate Polymers 0.000 abstract 5
- 239000007962 solid dispersion Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001125 extrusion Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000000683 nonmetastatic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques d'arn-509, qui peuvent être administrées à un mammifère, en particulier un humain, souffrant d'une maladie ou affection liée à un récepteur d'androgène (ar), en particulier un cancer, plus particulièrement un cancer de la prostate comprenant, mais non limité à, un cancer de la prostate résistant à la castration, un cancer de la prostate résistant à la castration métastatique, un cancer de la prostate résistant à la castration métastatique naïf de chimiothérapie, un cancer de la prostate hormonosensible biochimiquement récidivant, ou un cancer de la prostate résistant à la castration, non métastatique, à haut risque. Dans un aspect, ces formulations comprennent une dispersion solide d'arn-509, un copolymère de poly(méth)acrylate et hpmcas. Dans un aspect, la dispersion solide d'arn-509, d'un copolymère de poly(méth)acrylate et de hpmcas est susceptible d'être obtenue, en particulier est obtenue, par extrusion à l'état fondu d'un mélange comprenant arn-509, un copolymère de poly(méth)acrylate et hpmcas et ensuite, facultativement, le broyage dudit mélange extrudé à l'état fondu. Dans un aspect, la dispersion solide d'arn-509, d'un copolymère de poly(méth)acrylate et de hpmcas peut être obtenue, en particulier est obtenue, par séchage par pulvérisation un mélange comprenant arn-509, un copolymère de poly(méth)acrylate et hpmcas dans un solvant adapté.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196605 | 2014-12-05 | ||
| PCT/US2015/063671 WO2016090105A1 (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41111B1 true MA41111B1 (fr) | 2021-09-30 |
Family
ID=52006907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41111A MA41111B1 (fr) | 2014-12-05 | 2015-12-03 | Compositions anticancéreuses |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US10285948B2 (fr) |
| EP (2) | EP3226843B1 (fr) |
| JP (1) | JP6830892B2 (fr) |
| KR (1) | KR102387089B1 (fr) |
| CN (1) | CN106999432A (fr) |
| AR (1) | AR102925A1 (fr) |
| AU (1) | AU2015358497B2 (fr) |
| CA (1) | CA2969675C (fr) |
| CL (1) | CL2017001373A1 (fr) |
| CO (1) | CO2017005574A2 (fr) |
| CR (1) | CR20170218A (fr) |
| CY (1) | CY1124504T1 (fr) |
| DK (1) | DK3226843T3 (fr) |
| EA (1) | EA201791251A1 (fr) |
| ES (2) | ES2883187T3 (fr) |
| HR (1) | HRP20211140T1 (fr) |
| HU (1) | HUE054935T2 (fr) |
| IL (1) | IL252325A0 (fr) |
| LT (1) | LT3226843T (fr) |
| MA (1) | MA41111B1 (fr) |
| MD (1) | MD3226843T2 (fr) |
| MX (1) | MX381829B (fr) |
| MY (1) | MY192931A (fr) |
| NI (1) | NI201700068A (fr) |
| PH (1) | PH12017500979A1 (fr) |
| PL (1) | PL3226843T3 (fr) |
| PT (1) | PT3226843T (fr) |
| RS (1) | RS62421B1 (fr) |
| SG (1) | SG11201704386VA (fr) |
| SI (1) | SI3226843T1 (fr) |
| SM (1) | SMT202100454T1 (fr) |
| TW (1) | TWI709403B (fr) |
| UA (1) | UA123538C2 (fr) |
| WO (1) | WO2016090105A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| RS66323B1 (sr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals Inc | Sastavi protiv raka |
| MX381829B (es) | 2014-12-05 | 2025-03-13 | Aragon Pharmaceuticals Inc | Composiciones anticancerígenas. |
| UA129105C2 (uk) | 2017-10-16 | 2025-01-15 | Арагон Фармасьютикалз, Інк. | Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози |
| WO2020144649A1 (fr) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme |
| EP3918607A1 (fr) | 2019-01-30 | 2021-12-08 | Janssen Pharmaceutica NV | Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires |
| CN113365623B (zh) | 2019-01-30 | 2025-06-24 | 阿拉贡药品公司 | 用于治疗转移性去势敏感性前列腺癌的抗雄激素 |
| WO2020239478A1 (fr) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques |
| JP2023500935A (ja) | 2019-11-04 | 2023-01-11 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 重度の肝障害を有する対象における非転移性去勢抵抗性前立腺癌の治療のためのアンドロゲン受容体阻害剤 |
| WO2021245285A1 (fr) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (fr) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Méthodes de traitement du cancer de la prostate |
| WO2023152611A1 (fr) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide et relugolix pour le traitement du cancer de la prostate |
| WO2023209555A1 (fr) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate |
| CN121038790A (zh) | 2023-03-16 | 2025-11-28 | 拜耳消费者护理股份有限公司 | 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂 |
| WO2026052846A1 (fr) | 2024-09-09 | 2026-03-12 | Synthon B.V. | Formulation pharmaceutique comprenant de l'apalutamide |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ287434B6 (en) | 1992-03-31 | 2000-11-15 | British Tech Group | Use of steroids, substituted in position 17, steroids functioning as carcinostatics and pharmaceutical preparation containing thereof |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| AU2001232348A1 (en) | 2000-02-21 | 2001-08-27 | Takeda Chemical Industries Ltd. | Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same |
| SK10722003A3 (sk) | 2001-02-27 | 2004-02-03 | Astrazeneca Ab | Farmaceutická formulácia obsahujúca bicalutamid v pevnej disperzii s enterickým polymérom a jej použitie |
| WO2002080902A1 (fr) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Composition pharmaceutique solide contenant 4-cyano-trifluoro-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropiono-m-toluidiure et pvp |
| PL368587A1 (en) | 2001-06-22 | 2005-04-04 | Pfizer Products Inc. | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |
| SE0103424D0 (sv) | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| PL371593A1 (en) | 2002-02-01 | 2005-06-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| JPWO2003077827A1 (ja) | 2002-03-19 | 2005-07-14 | 日本新薬株式会社 | 医薬固体分散体の製造方法 |
| WO2005055987A1 (fr) | 2003-12-15 | 2005-06-23 | Council Of Scientific & Industrial Research | Compositions pharmaceutiques au gout masque comportant une medicament amer et un polymere sensible au ph |
| EP2656842B1 (fr) | 2006-03-27 | 2016-08-10 | The Regents of The University of California | Modulateur de récepteur androgène pour le traitement du cancer de la prostate et de maladies associées au récepteur androgène |
| EA031116B1 (ru) * | 2009-04-03 | 2018-11-30 | Ф. Хоффманн-Ля Рош Аг | КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ |
| HUE037389T2 (hu) | 2010-02-16 | 2018-08-28 | Aragon Pharmaceuticals Inc | Androgén receptor modulátorok és alkalmazásaik |
| CN102525876B (zh) * | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| US10071945B2 (en) | 2011-06-15 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (fr) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Inhibiteur de mtor anticancéreux et combinaison anti-androgène |
| EP3922629A1 (fr) | 2012-06-07 | 2021-12-15 | Aragon Pharmaceuticals, Inc. | Formes cristallines d'un modulateur de récepteur d'androgène |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| BR112015002055A2 (pt) | 2012-08-24 | 2017-07-04 | Dow Global Technologies Llc | acetato succinato de hidroxialquil metil celulose, composição, dispersão sólida, processo para produzir uma dispersão sólida, forma de dosagem e cápsula de envoltório |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| EP4450130A3 (fr) | 2012-09-11 | 2025-01-08 | Medivation Prostate Therapeutics LLC | Formulations d'enzalutamide |
| ES2836424T3 (es) * | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| CA3105575A1 (fr) | 2013-01-15 | 2014-07-24 | Aragon Pharmaceuticals, Inc. | Modulateur du recepteur des androgenes et ses utilisations |
| UA116004C2 (uk) | 2013-01-22 | 2018-01-25 | Ф. Хоффманн-Ля Рош Аг | Фармацевтична композиція з покращеною біодоступністю |
| JP2016514707A (ja) | 2013-03-15 | 2016-05-23 | アイシューティカ インク．Ｉｃｅｕｔｉｃａ Ｉｎｃ． | アビラテロン酢酸エステル製剤 |
| WO2014167428A2 (fr) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | 4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe |
| WO2015023710A1 (fr) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes |
| WO2015116696A1 (fr) * | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Thérapies de combinaison et procédés d'utilisation associés pour le traitement du cancer |
| EP3102183A1 (fr) * | 2014-02-05 | 2016-12-14 | LEK Pharmaceuticals d.d. | Compositions pharmaceutiques solides d'antagonistes du récepteur des androgènes |
| CN111423513A (zh) | 2014-02-06 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 白介素-2融合蛋白和其用途 |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| MX381829B (es) | 2014-12-05 | 2025-03-13 | Aragon Pharmaceuticals Inc | Composiciones anticancerígenas. |
| ES2839128T3 (es) | 2014-12-05 | 2021-07-05 | Aragon Pharmaceuticals Inc | Composiciones anticancerosas |
| RS66323B1 (sr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals Inc | Sastavi protiv raka |
| UA124154C2 (uk) * | 2016-06-03 | 2021-07-28 | Арагон Фармасьютікалз, Інк. | Протиракові композиції |
-
2015
- 2015-12-03 MX MX2017007206A patent/MX381829B/es unknown
- 2015-12-03 CR CR20170218A patent/CR20170218A/es unknown
- 2015-12-03 HR HRP20211140TT patent/HRP20211140T1/hr unknown
- 2015-12-03 KR KR1020177018243A patent/KR102387089B1/ko active Active
- 2015-12-03 CN CN201580066235.3A patent/CN106999432A/zh active Pending
- 2015-12-03 DK DK15820351.3T patent/DK3226843T3/da active
- 2015-12-03 EA EA201791251A patent/EA201791251A1/ru unknown
- 2015-12-03 ES ES15820351T patent/ES2883187T3/es active Active
- 2015-12-03 EP EP15820351.3A patent/EP3226843B1/fr active Active
- 2015-12-03 PT PT158203513T patent/PT3226843T/pt unknown
- 2015-12-03 MY MYPI2017701986A patent/MY192931A/en unknown
- 2015-12-03 JP JP2017529774A patent/JP6830892B2/ja active Active
- 2015-12-03 RS RS20211035A patent/RS62421B1/sr unknown
- 2015-12-03 UA UAA201707015A patent/UA123538C2/uk unknown
- 2015-12-03 CA CA2969675A patent/CA2969675C/fr active Active
- 2015-12-03 AU AU2015358497A patent/AU2015358497B2/en active Active
- 2015-12-03 US US15/533,229 patent/US10285948B2/en active Active
- 2015-12-03 PL PL15820351T patent/PL3226843T3/pl unknown
- 2015-12-03 WO PCT/US2015/063671 patent/WO2016090105A1/fr not_active Ceased
- 2015-12-03 LT LTEP15820351.3T patent/LT3226843T/lt unknown
- 2015-12-03 MD MDE20170154T patent/MD3226843T2/ro not_active IP Right Cessation
- 2015-12-03 MA MA41111A patent/MA41111B1/fr unknown
- 2015-12-03 HU HUE15820351A patent/HUE054935T2/hu unknown
- 2015-12-03 EP EP21175525.1A patent/EP3925598B1/fr active Active
- 2015-12-03 TW TW104140459A patent/TWI709403B/zh not_active IP Right Cessation
- 2015-12-03 SM SM20210454T patent/SMT202100454T1/it unknown
- 2015-12-03 SG SG11201704386VA patent/SG11201704386VA/en unknown
- 2015-12-03 ES ES21175525T patent/ES3019912T3/es active Active
- 2015-12-03 SI SI201531686T patent/SI3226843T1/sl unknown
- 2015-12-04 AR ARP150103981A patent/AR102925A1/es unknown
-
2017
- 2017-05-16 IL IL252325A patent/IL252325A0/en unknown
- 2017-05-26 PH PH12017500979A patent/PH12017500979A1/en unknown
- 2017-05-29 CL CL2017001373A patent/CL2017001373A1/es unknown
- 2017-06-02 NI NI201700068A patent/NI201700068A/es unknown
- 2017-06-05 CO CONC2017/0005574A patent/CO2017005574A2/es unknown
-
2019
- 2019-03-19 US US16/357,821 patent/US11224575B2/en active Active
-
2021
- 2021-03-15 US US17/201,811 patent/US11911511B2/en active Active
- 2021-08-13 CY CY20211100730T patent/CY1124504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41111B1 (fr) | Compositions anticancéreuses | |
| MA41107B1 (fr) | Compositions anti-cancéreuses | |
| MA41108A (fr) | Compositions anticancéreuses | |
| PH12018502334A1 (en) | Anticancer compositions | |
| MA44693B1 (fr) | Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers | |
| MA44551A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers | |
| MA37809A1 (fr) | Administration de médicament biodégradable pour compositions hydrophobes | |
| MA33405B1 (fr) | Anticorps anti-axl | |
| EA202191914A1 (ru) | Бесследные линкеры и их белок-конъюгаты | |
| TH170798A (th) | องค์ประกอบต้านมะเร็ง | |
| MA41664A1 (fr) | Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers |